FDA Sharpens Its Pencil and Oversight Tools on Global Clinical Trial Data
The FDA has signaled heightened scrutiny of global clinical trial data, including greater use of bioresearch monitoring inspections and increased transparency around inspection findings and access barriers. Sponsors relying on ex-US clinical data must …